Terms: = Prostate cancer AND MYCL, LMYC, 4610, MYCL1, ENSG00000116990 AND Treatment
6 results:
1. Daily physical activity monitoring in older adults with metastatic prostate cancer on active treatment: Feasibility and associations with toxicity.
Feng G; Parthipan M; Breunis H; Timilshina N; Soto-Perez-de-Celis E; Mina DS; Emmenegger U; Finelli A; Krzyzanowska MK; Clarke H; Puts M; Alibhai SMH
J Geriatr Oncol; 2023 Sep; 14(7):101576. PubMed ID: 37421787
[TBL] [Abstract] [Full Text] [Related]
2. Longitudinal CTCs gene expression analysis on metastatic castration-resistant prostate cancer patients treated with docetaxel reveals new potential prognosis markers.
Pereira-Veiga T; González-Conde M; León-Mateos L; Piñeiro-Cid R; Abuín C; Muinelo-Romay L; Martínez-Fernández M; Brea Iglesias J; García González J; Anido U; Aguín-Losada S; Cebey V; Costa C; López-López R
Clin Exp Metastasis; 2021 Apr; 38(2):239-251. PubMed ID: 33635497
[TBL] [Abstract] [Full Text] [Related]
3. Genomic Alterations in Cell-Free DNA and Enzalutamide Resistance in Castration-Resistant prostate cancer.
Wyatt AW; Azad AA; Volik SV; Annala M; Beja K; McConeghy B; Haegert A; Warner EW; Mo F; Brahmbhatt S; Shukin R; Le Bihan S; Gleave ME; Nykter M; Collins CC; Chi KN
JAMA Oncol; 2016 Dec; 2(12):1598-1606. PubMed ID: 27148695
[TBL] [Abstract] [Full Text] [Related]
4. Comprehensive serial molecular profiling of an "N of 1" exceptional non-responder with metastatic prostate cancer progressing to small cell carcinoma on treatment.
Kadakia KC; Tomlins SA; Sanghvi SK; Cani AK; Omata K; Hovelson DH; Liu CJ; Cooney KA
J Hematol Oncol; 2015 Oct; 8():109. PubMed ID: 26444865
[TBL] [Abstract] [Full Text] [Related]
5. prostate-specific antigen (PSA) rate of decline post external beam radiotherapy predicts prostate cancer death.
Shi Z; Pinnock CB; Kinsey-Trotman S; Borg M; Moretti KL; Walsh S; Kopsaftis T
Radiother Oncol; 2013 May; 107(2):129-33. PubMed ID: 23623726
[TBL] [Abstract] [Full Text] [Related]
6. Genetic variant as a selection marker for anti-prostate stem cell antigen immunotherapy of bladder cancer.
Kohaar I; Porter-Gill P; Lenz P; Fu YP; Mumy A; Tang W; Apolo AB; Rothman N; Baris D; Schned AR; Ylaya K; Schwenn M; Johnson A; Jones M; Kida M; Silverman DT; Hewitt SM; Moore LE; Prokunina-Olsson L
J Natl Cancer Inst; 2013 Jan; 105(1):69-73. PubMed ID: 23266392
[TBL] [Abstract] [Full Text] [Related]
